Edge Therapeutics Inc (NASDAQ:EDGE) CEO Brian A. Leuthner sold 2,500 shares of the company’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $9.92, for a total value of $24,800.00. Following the completion of the sale, the chief executive officer now owns 95,236 shares of the company’s stock, valued at $944,741.12. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of Edge Therapeutics Inc (NASDAQ EDGE) traded down $0.21 during trading on Tuesday, hitting $9.55. The stock had a trading volume of 78,884 shares, compared to its average volume of 62,801. Edge Therapeutics Inc has a twelve month low of $7.30 and a twelve month high of $13.50. The company has a current ratio of 8.34, a quick ratio of 8.34 and a debt-to-equity ratio of 0.20.

Edge Therapeutics (NASDAQ:EDGE) last announced its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.37) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.48) by $0.11. equities analysts forecast that Edge Therapeutics Inc will post -1.7 earnings per share for the current fiscal year.

Several institutional investors have recently made changes to their positions in the company. Schwab Charles Investment Management Inc. lifted its stake in shares of Edge Therapeutics by 0.7% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 75,279 shares of the biotechnology company’s stock valued at $773,000 after purchasing an additional 532 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in shares of Edge Therapeutics by 16.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 11,959 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 1,733 shares during the last quarter. California State Teachers Retirement System lifted its stake in shares of Edge Therapeutics by 7.7% in the 2nd quarter. California State Teachers Retirement System now owns 35,167 shares of the biotechnology company’s stock valued at $361,000 after purchasing an additional 2,500 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of Edge Therapeutics by 19.1% in the 2nd quarter. Rhumbline Advisers now owns 19,960 shares of the biotechnology company’s stock valued at $205,000 after purchasing an additional 3,195 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Edge Therapeutics by 26.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,114 shares of the biotechnology company’s stock valued at $186,000 after purchasing an additional 3,764 shares during the last quarter. 50.26% of the stock is currently owned by institutional investors and hedge funds.

Several brokerages have issued reports on EDGE. Zacks Investment Research upgraded Edge Therapeutics from a “sell” rating to a “buy” rating and set a $12.00 target price for the company in a report on Monday, November 6th. BidaskClub cut Edge Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 14th.

ILLEGAL ACTIVITY WARNING: This story was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.americanbankingnews.com/2017/12/05/edge-therapeutics-inc-edge-ceo-sells-24800-00-in-stock.html.

About Edge Therapeutics

Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.

Insider Buying and Selling by Quarter for Edge Therapeutics (NASDAQ:EDGE)

Receive News & Ratings for Edge Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.